Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Keyword(s):
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews important research in thoracic cancers presented at the 2021 ASCO Annual Meeting, including atezolizumab in early-stage lung cancer, the addition of doublet chemotherapy to doublet immunotherapy in advanced-stage NSCLC, the first-in-class KRAS G12C inhibitor sotorasib, and the combination of amivantamab and lazertinib. Coverage provided by The ASCO Post.
2007 ◽
Vol 41
(4)
◽
pp. 266-266
Keyword(s):
Keyword(s):
1996 ◽
Vol 2
(4)
◽
pp. 203-206
◽
2014 ◽
Vol 90
(1)
◽
pp. S589-S590